Prime Medicine Inc Revenue Growth Rates (PRME), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Prime Medicine Inc   (NASDAQ: PRME)
 

PRME's Revenue Growth by Quarter and Year

Prime Medicine Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PRME/growth
https://api.csimarket.com/api/v1/companies/PRME/fundamentals
https://api.csimarket.com/api/v1/companies/PRME/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PRME Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.21
2nd Quarter June 1.15
1st Quarter March 0.86
FY 6.22





PRME Revenue third quarter 2026 Y/Y Growth Comment
Prime Medicine Inc achieved in the third quarter 2026, above Company average Revenue surge of 242.52% year on year, to $ 4.21 millions.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Revenue growth. While Prime Medicine Inc ' s Revenue doubling of 242.52% ranks overall at the positon no. 2521 in the third quarter 2026.


PRME Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 242.52 %
2nd Quarter June 2.68 %
1st Quarter March -40.69 %
FY   -

Financial Statements
Prime Medicine Inc 's third quarter 2026 Revenue $ 4.21 millions PRME's Income Statement
Prime Medicine Inc 's third quarter 2025 Revenue $ 1.23 millions Quarterly PRME's Income Statement


PRME Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 266.35 %
2nd Quarter June 33.72 %
1st Quarter March 2.38 %
FY (Year on Year)   -


Back to PRME Growth rate Comparisons >> Back to PRME Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #363
Overall #2521

Revenue Y/Y Growth Statistics
High Average Low
486.12 % 106.58 % -61.61 %
(Jun 30 2026)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #363
Overall #2521
Revenue Y/Y Growth Statistics
High Average Low
486.12 % 106.58 % -61.61 %
(Jun 30 2026)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Prime Medicine Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
944.5 % 100.38 % -100 %
(Dec 31 2024)  


PRME's III. Quarter Q/Q Revenue Comment
Prime Medicine Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 266.35%, to $ 4.21 millions, from $1.15 millions in the second quarter.
PRME is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Prime Medicine Inc 's Revenue growth quarter on quarter, overall rank is 338.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #79
Overall #338
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #79
Overall #338
Revenue Q/Q Growth Statistics
High Average Low
944.5 % 100.38 % -100 %
(Dec 31 2024)  


PRME's III. Quarter Q/Q Revenue Comment
Prime Medicine Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 266.35%, to $ 4.21 millions, from $1.15 millions in the second quarter.
PRME is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Prime Medicine Inc 's Revenue growth quarter on quarter, overall rank is 338.


Prime Medicine Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 7.06
Y / Y Revenue Growth (TTM) 18.14 %
Year on Year Revenue Growth Overall Ranking # 3388
Seqeuential Revenue Change (TTM) 73.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 849


Cumulative Revenue growth Comment
Prime Medicine Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.14% year on year, to $ 7 millions if the fiscal year would have ended in Sep 30 2026.
Prime Medicine Inc 's trailing twelve months Revenue growth was higher than company's average -17.9% and higher than -17.9% growth in Jun 30 2026.

In the Healthcare sector 452 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3388.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 453
Overall # 3388

Revenue TTM Y/Y Growth Statistics
High Average Low
-17.9 %
 -17.9 %
-17.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 175
S&P 500 # 849
Cumulative Revenue growth Comment
Prime Medicine Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.14% year on year, to $ 7 millions if the fiscal year would have ended in Sep 30 2026.
Prime Medicine Inc 's trailing twelve months Revenue growth was higher than company's average -17.9% and higher than -17.9% growth in Jun 30 2026.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 73.36 % increase from $4.07 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 452 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3388.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 453
Overall # 3388

Revenue TTM Y/Y Growth Statistics
High Average Low
-17.9 %
-17.9 %
-17.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 175
S&P 500 # 849




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRME's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions


About Prime Medicine Inc Revenue Growth Rates (PRME), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Prime Medicine Inc (CIK 1894562).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-073392
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Prime Medicine Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.